Stock Analysis Report

Header cover image

Excelsior Biopharma

Market Cap


Last Updated

2021/06/18 09:03 UTC

Data Sources

Company Financials

Executive Summary

Excelsior Biopharma Inc. develops pharmaceutical products in Taiwan. More Details

Snowflake Analysis

Excellent balance sheet and fair value.

Share Price & News

How has Excelsior Biopharma's share price performed over time and what events caused price changes?

Latest Share Price and Events

Stable Share Price: 6496 is less volatile than 75% of TW stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: 6496's weekly volatility (4%) has been stable over the past year.

Market Performance

7 Day Return




TW Healthcare


TW Market

1 Year Return




TW Healthcare


TW Market

Return vs Industry: 6496 underperformed the TW Healthcare industry which returned 11.8% over the past year.

Return vs Market: 6496 underperformed the TW Market which returned 48.5% over the past year.

Shareholder returns

7 Day2.8%-0.1%1.3%
30 Day5.3%3.1%8.1%
90 Day2.8%1.1%8.0%
1 Year-10.3%-12.9%15.3%11.8%53.3%48.5%
3 Year-25.0%-38.6%46.9%32.6%75.9%55.7%
5 Year-43.8%-58.0%78.5%48.6%140.8%97.9%

Long-Term Price Volatility Vs. Market

How volatile is Excelsior Biopharma's share price compared to the market and industry in the last 5 years?

Simply Wall St News


Is Excelsior Biopharma undervalued compared to its fair value and its price relative to the market?


Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: 6496 (NT$29) is trading below our estimate of fair value (NT$257.16)

Significantly Below Fair Value: 6496 is trading below fair value by more than 20%.

Price To Earnings Ratio

PE vs Industry: 6496 is poor value based on its PE Ratio (53.6x) compared to the TW Healthcare industry average (16.7x).

PE vs Market: 6496 is poor value based on its PE Ratio (53.6x) compared to the TW market (17.6x).

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 6496's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: 6496 is good value based on its PB Ratio (1x) compared to the TW Healthcare industry average (1.9x).

Future Growth

How is Excelsior Biopharma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?


Forecasted Healthcare industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Excelsior Biopharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has Excelsior Biopharma performed over the past 5 years?


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 6496 has high quality earnings.

Growing Profit Margin: 6496's current net profit margins (1.8%) are lower than last year (4.5%).

Past Earnings Growth Analysis

Earnings Trend: 6496's earnings have declined by 21.9% per year over the past 5 years.

Accelerating Growth: 6496's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 6496 had negative earnings growth (-62.6%) over the past year, making it difficult to compare to the Healthcare industry average (-2.6%).

Return on Equity

High ROE: 6496's Return on Equity (1.9%) is considered low.

Financial Health

How is Excelsior Biopharma's financial position?

Financial Position Analysis

Short Term Liabilities: 6496's short term assets (NT$1.7B) exceed its short term liabilities (NT$334.4M).

Long Term Liabilities: 6496's short term assets (NT$1.7B) exceed its long term liabilities (NT$365.7M).

Debt to Equity History and Analysis

Debt Level: 6496's debt to equity ratio (22.1%) is considered satisfactory.

Reducing Debt: 6496's debt to equity ratio has increased from 4.1% to 22.1% over the past 5 years.

Debt Coverage: 6496's debt is well covered by operating cash flow (106%).

Interest Coverage: 6496's interest payments on its debt are well covered by EBIT (11.6x coverage).

Balance Sheet


What is Excelsior Biopharma current dividend yield, its reliability and sustainability?


Current Dividend Yield

Upcoming Dividend Payment

TodayJun 18 2021Ex Dividend DateJul 13 2021Dividend Pay DateAug 06 202124 days from Ex DividendBuy in the next 24 days to receive the upcoming dividend

Dividend Yield vs Market

Notable Dividend: 6496's dividend (3.45%) is higher than the bottom 25% of dividend payers in the TW market (2%).

High Dividend: 6496's dividend (3.45%) is low compared to the top 25% of dividend payers in the TW market (5.01%).

Stability and Growth of Payments

Stable Dividend: 6496 has been paying a dividend for less than 10 years and during this time payments have been volatile.

Growing Dividend: 6496 has only been paying a dividend for 6 years, and since then payments have fallen.

Current Payout to Shareholders

Dividend Coverage: With its high payout ratio (184.8%), 6496's dividend payments are not well covered by earnings.

Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.

Next Steps


How experienced are the management team and are they aligned to shareholders interests?


Average board tenure


Joseph Chen

no data


Mr. Joseph Chen is the Chairman, President and General Manager at Excelsior Biopharma Inc. and has also been a Director since June 16, 2003. National Chengchi University – EMBA in Graduate Institute of Tec...

Board Members

Experienced Board: 6496's board of directors are considered experienced (6.3 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Company Information

Excelsior Biopharma Inc.'s company bio, employee growth, exchange listings and data sources

Key Information

  • Name: Excelsior Biopharma Inc.
  • Ticker: 6496
  • Exchange: TPEX
  • Founded: 1988
  • Industry: Health Care Distributors
  • Sector: Healthcare
  • Market Cap: NT$1.353b
  • Shares outstanding: 46.67m
  • Website:


  • Excelsior Biopharma Inc.
  • No.3, Park Street
  • 14th Floor - 6
  • Taipei
  • Taiwan



Excelsior Biopharma Inc. develops pharmaceutical products in Taiwan. The company offers prescription drugs, over-the-counter drugs, medical devices, healthcare food products, medical supplies, and skin pro...

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/06/18 09:03
End of Day Share Price2021/06/17 00:00
Annual Earnings2020/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.